Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Repeat Dose Nasal Allergen Challenge

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2012 by McMaster University.
Recruitment status was:  Recruiting
St. Joseph's Healthcare Hamilton
Information provided by (Responsible Party):
McMaster University Identifier:
First received: April 23, 2010
Last updated: October 31, 2012
Last verified: October 2012
What happens in the nose during an allergic reaction? Are there changes that a new drug could treat? What is the best way to test new drugs?The response of the nose to being exposed to cat allergen in someone who is allergic to cats. Symptoms, level of nasal blockage and cell and chemical changes that occur in the nose will be studied before and after being exposed to cat allergen. The investigators will also to see if giving repeated doses of allergen increases the response.Allergic rhinitis is a very common illness. There are over 500 million patients worldwide. It can increase the severity of associated asthma. Currently available drugs do not completely treat the symptoms. New treatments need to be found. A way of testing these drugs is very important. This study will investigate causes of the symptoms that occur in allergic rhinitis. It will also validate a proposed model to test new drugs. the Study Hypothesis is that a model of nasal allergen challenge shows an increased response (priming) with repeat challenges as determined by changes in nasal peak inspiratory flow.

Condition Intervention
Allergic Rhinitis
Other: Allergen
Other: Placebo challenge

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Basic Science
Official Title: Repeat Dose Nasal Allergen Challenge: Development of a Model to Investigate the Cellular and Inflammatory Changes That Occur in Allergic Rhinitis

Further study details as provided by McMaster University:

Primary Outcome Measures:
  • Change in peak nasal inspiratory flow following repeat allergen challenge [ Time Frame: 1 year ]
    The peak nasal inspiratory flow will be measured using a hand-held peak flow meter, and changes will be measured following repeated allergen challenge.

Estimated Enrollment: 30
Study Start Date: April 2010
Estimated Study Completion Date: April 2013
Estimated Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Allergen Other: Allergen
Allergen nasal challenge
Placebo Comparator: Placebo Other: Placebo challenge
Placebo nasal challenge


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and female subjects aged over 18 able to understand and sign the written consent form.
  2. Able to comply with study procedures and protocol.
  3. Positive skin prick test (wheal difference ≥ 3mm compared to negative control) to cat at or within 12 months preceding the screening visit.
  4. Clear history of nasal symptoms on exposure to cats.
  5. Otherwise healthy with no other health problems, other than mild asthma controlled by intermittent β2-agonist use, that may prevent the subject participating in the study.

Exclusion Criteria:

  1. Presence of perennial rhinitis or seasonal allergic rhinitis.
  2. TNSS < 2 at screening
  3. Viral URTI within the 2 weeks prior to screening.
  4. Current smoker or history of smoking within the previous 3 months.
  5. Presence of any structural nasal abnormalities or nasal polyps on examination, a history of frequent nose bleeding, nasal surgery within the previous 3 months.
  6. Use of concomitant medication that could affect responses to nasal challenge (e.g. corticosteroids, decongestants, anti-histamines) or any other nasally applied medication within 2 weeks prior to screening.
  7. Participation in any other clinical trials within the previous 3 months.
  8. Use of inhaled corticosteroids within the 2 months prior to screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01110837

Contact: Helen Neighbour, MB BS PhD 905-522-1155 ext 32145

Canada, Ontario
St Joseph's Healthcare Recruiting
Hamitlon, Ontario, Canada, L8N 4A6
Sponsors and Collaborators
McMaster University
St. Joseph's Healthcare Hamilton
Principal Investigator: Helen Neighbour, MB BS McMaster University
  More Information

Responsible Party: McMaster University Identifier: NCT01110837     History of Changes
Other Study ID Numbers: #09-3232
Study First Received: April 23, 2010
Last Updated: October 31, 2012

Keywords provided by McMaster University:
Allergic rhinitis

Additional relevant MeSH terms:
Rhinitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on April 24, 2017